Table 2 Relations between FGF-23 concentrations and different combinations of anti-diabetes therapy
Yes | No | P-value | |
|---|---|---|---|
SGLT-2 inhibitor only (n = 27) | 71 (61–94) | 75 (58–91) | 0.89 |
GLP-1 analogue only (n = 20) | 68 (55–87) | 81 (60–98) | 0.04* |
SGLT-2 inhibitor + GLP-1 analogue (n = 16) | 74 (57–91) | 74 (61–92) | 0.86 |
Insulin only (n = 67) | 68 (55–86) | 75 (60–94) | 0.03 |
Insulin + SGLT-2 inhibitor (n = 28) | 75 (62–90) | 74 (57–91) | 0.62 |
Insulin + GLP-1 analogue (n = 40) | 72 (58–88) | 83 (60–99) | 0.04 |
Insulin + SGLT-2 inhibitor + GLP-1 analogue (n = 11) | 74 (58–93) | 75 (58–91) | 0.76 |